CN1713888B - 用于治疗被太阳损伤的皮肤的膏霜 - Google Patents
用于治疗被太阳损伤的皮肤的膏霜 Download PDFInfo
- Publication number
- CN1713888B CN1713888B CN028131169A CN02813116A CN1713888B CN 1713888 B CN1713888 B CN 1713888B CN 028131169 A CN028131169 A CN 028131169A CN 02813116 A CN02813116 A CN 02813116A CN 1713888 B CN1713888 B CN 1713888B
- Authority
- CN
- China
- Prior art keywords
- weight
- cream
- alpha
- lipoic acid
- skin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000006071 cream Substances 0.000 title claims abstract description 46
- 229960002663 thioctic acid Drugs 0.000 claims abstract description 29
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims abstract description 19
- 238000000034 method Methods 0.000 claims abstract description 10
- 230000000699 topical effect Effects 0.000 claims abstract description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 9
- 230000001815 facial effect Effects 0.000 claims description 8
- 150000003254 radicals Chemical class 0.000 claims description 6
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims description 4
- 229960004203 carnitine Drugs 0.000 claims description 4
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 3
- 230000007246 mechanism Effects 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 230000008832 photodamage Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 6
- 230000008569 process Effects 0.000 abstract description 4
- 206010051246 Photodermatosis Diseases 0.000 abstract description 3
- 239000004480 active ingredient Substances 0.000 abstract description 3
- 150000001875 compounds Chemical class 0.000 abstract description 2
- 230000000087 stabilizing effect Effects 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 22
- AGBQKNBQESQNJD-UHFFFAOYSA-N alpha-Lipoic acid Natural products OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 18
- 235000019136 lipoic acid Nutrition 0.000 description 18
- AGBQKNBQESQNJD-SSDOTTSWSA-N (R)-lipoic acid Chemical compound OC(=O)CCCC[C@@H]1CCSS1 AGBQKNBQESQNJD-SSDOTTSWSA-N 0.000 description 16
- 230000003078 antioxidant effect Effects 0.000 description 13
- 239000003963 antioxidant agent Substances 0.000 description 10
- 235000006708 antioxidants Nutrition 0.000 description 10
- RDHQFKQIGNGIED-MRVPVSSYSA-N O-acetyl-L-carnitine Chemical compound CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C RDHQFKQIGNGIED-MRVPVSSYSA-N 0.000 description 9
- 229960001009 acetylcarnitine Drugs 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 5
- 210000002615 epidermis Anatomy 0.000 description 5
- 230000001804 emulsifying effect Effects 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 210000003470 mitochondria Anatomy 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 230000002438 mitochondrial effect Effects 0.000 description 3
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 229910052710 silicon Inorganic materials 0.000 description 3
- 239000010703 silicon Substances 0.000 description 3
- 229960001727 tretinoin Drugs 0.000 description 3
- 229940040064 ubiquinol Drugs 0.000 description 3
- QNTNKSLOFHEFPK-UPTCCGCDSA-N ubiquinol-10 Chemical compound COC1=C(O)C(C)=C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)C(O)=C1OC QNTNKSLOFHEFPK-UPTCCGCDSA-N 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- IZFHEQBZOYJLPK-SSDOTTSWSA-N (R)-dihydrolipoic acid Chemical compound OC(=O)CCCC[C@@H](S)CCS IZFHEQBZOYJLPK-SSDOTTSWSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- KJTLQQUUPVSXIM-ZCFIWIBFSA-N (R)-mevalonic acid Chemical group OCC[C@](O)(C)CC(O)=O KJTLQQUUPVSXIM-ZCFIWIBFSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 235000011437 Amygdalus communis Nutrition 0.000 description 1
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- XPJVKCRENWUEJH-UHFFFAOYSA-N Isobutylparaben Chemical compound CC(C)COC(=O)C1=CC=C(O)C=C1 XPJVKCRENWUEJH-UHFFFAOYSA-N 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 241000220304 Prunus dulcis Species 0.000 description 1
- 230000002292 Radical scavenging effect Effects 0.000 description 1
- 239000004902 Softening Agent Substances 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 230000002079 cooperative effect Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 229940008099 dimethicone Drugs 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000027721 electron transport chain Effects 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- -1 hydroxyl radical free radical Chemical class 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 230000036555 skin type Effects 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/004—Aftersun preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/35—Ketones, e.g. benzophenone
- A61K8/355—Quinones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4986—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with sulfur as the only hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/66—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Birds (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
- Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
Abstract
本发明涉及在权利要求1前序部分描述的那类用于局部治疗由某些过程引起的可见的光损伤性皮肤的膏霜,这些过程包括自由基的影响,并且此膏霜也会影响细胞的能量产出,其中膏霜的活性成分由稳定的膏霜基质承载。此膏霜的特征在于含0.5-7%重量的d,l-α-硫辛酸,0.05-0.5%重量的辅酶Q-10,0.001-3%重量的乙酰-l-肉毒碱盐酸盐,它们组成活性成分,由此具有化合物协同作用。
Description
本发明涉及用于局部治疗由某些过程引起的光损伤性皮肤的面部膏霜,这些过程包括自由基的影响。
本发明也涉及构成用于上述面部膏霜的基础处方的赋形剂,其具有分散和乳化膏霜的活性成分和添加保湿、软化、稳定、防腐能力,且使霜膏具有皮肤渗透性质,和涉及在制备上述面部膏霜中在赋形剂里分散和乳化d,1-α-硫辛酸的方法。
在每一时代和文明中,人类已经使用了各种不同的方法来改善他们的面貌,并且年轻的外表已经变得愈加地理想化。一个人的个人特质与她的面容有很大的关系。因此,面霜和化妆品被设计来强调和加强年轻的容貌并隐藏和减少岁月的痕迹。年轻的容貌也用晒后的颜色强调。
当暴露于阳光和UV-射线时,皮肤的细胞会被晒伤,这最终会导致可见的损伤-光损伤性皮肤-其表现为局部放大的色素沉着,松弛,细纹,皱纹,扩大的毛孔,眼袋和在皮脂腺中的黑色和暗色堵塞的发展。吸烟,不适当的营养,疾病和压力会使光损伤性皮肤恶化。
如今人们普遍承认的是光损伤性皮肤是由已知称作自由基的氧和氮的短期中间产物引起的,它们主要产生于细胞的线粒体中。自由基会损伤细胞的遗传物质和线粒体并且也会减少线粒体的能量产出。从自由基的普遍出现以来,在细胞水平的特定的防御机制是与生俱来的,包括抗氧化营养物质、修复酶类和各种的调试机制的共同作用。
未修复的损伤会累积,导致能量产出的逐渐减少和自由基产出的增加。
人们已经作了不懈的努力以通过局部应用抗氧化的化合物来影响皮肤和阻止或延迟光损伤性皮肤的发展。一个实例是通过使用抗氧化剂维生素C和E来削弱对光线损害的响应。
也有重要的证据显示抗氧化剂能在细胞水平作为抗炎剂,即通过 抑制与酶(激酶)相关的某些炎性因子的激活,以及通过抑制例如核因子κB的转录因子的激活。抗氧剂在皮肤上的使用会阻止促炎细胞因子基因的表达,这些抗炎细胞因子例如TNF-α,IL-1,IL-2,IL-6和IL-8,它们对于暴露于阳光的最初的炎性反应都是很重要的。
大量现有的霜膏中包含具有自由基清除性质的活性成分。视黄酸就是一种这样的成分,它是迄今为止唯一的达成科学一致意见的成分,即在某些方面它能对光损伤性皮肤起积极的作用。
在如下几篇专利中公开了其它的膏霜,WO00/53176中公开的膏霜包含硫辛酸和氨基酸半胱氨酸的组合,EP0945127中公开的膏霜包含乙酰肉毒碱和其它抗氧剂(例如硫辛酸)的组合,DE19806947A1中公开的膏霜包含乙酰肉毒碱和Q-10,US5912272中公开的膏霜包含Q-10。而且也有一些包含连带地有助于细胞能量产出的抗氧剂的膏霜。这些膏霜所共有的特点是它们被声称对于与衰老有关的皮肤变化起作用,这一点很难被说成是唯一的。上面提及的膏霜中均未声称在具有平衡比例的硫辛酸,Q-10和乙酰肉毒碱之间具有协同作用。
本发明的目的是获得一种膏霜,其具有减少光损伤性皮肤的可见性痕迹至相当可观的程度的能力。这是通过使用按照本发明制备的膏霜获得的,它的特性在权利要求1中描述。
像视黄酸一样,此膏霜减少光损伤性皮肤的可见性痕迹而不引起视黄酸的典型的副作用。
最初,一些人可能对于在这种膏霜中的d,1-α-硫辛酸的量具有强烈的反应,然而本发明允许在膏霜中使用较少量的d,1-α-硫辛酸。此膏霜具有在权利要求3中提及的特性。
本发明的另一个目的是获得一种赋形剂,其能包封和稳定膏霜中的活性物质,并且在经过足够长的时期后它们仍能以理想的形式存在。该赋形剂具有在权利要求4中提及的性质。
本发明的另一目的是获得一种方法,当生产膏霜时利用此方法来在赋形剂中分散和乳化d,1-α-硫辛酸。这是通过具有权利要求5的特性的方法获得的。
硫辛酸是有效的脂溶性和水溶性抗氧剂,它能通过植物也能通过动物被合成。它的氧化型和还原型(二氢硫辛酸)都有抗氧化活性。硫辛酸有效地清除,尤其是羟基自由基、单态氧和一氧化氮,并作为细胞内的炎性应答的调节剂。至少从理论上讲,分子的大小和溶解性应该建立更好的条件来达到在皮肤上的临床效果(与其它已知的抗氧剂相比)。在皮肤上局部施用的硫辛酸会快速地穿透表皮的角质层并且能在约4小时内在真皮内被发现。硫辛酸能被容易地转化成它的还原型,并且在外部施用硫辛酸后,硫辛酸和二氢硫辛酸在细胞内和细胞外水平的作用都是明显的。
与硫辛酸一样,辅酶Q-10也能通过植物和动物被合成。人类Q-10的自我合成通过甲羟戊酸链发生,在那里合成一些脂肪和脂肪类似物质。Q-10以它的还原形式(ubiquinol)作为抗氧剂。与其它抗氧剂相比,ubiquinol的浓度在表皮中是特别高的,与在真皮中相反。这能被解释为对于通过ubiquinol的表皮的抗氧剂保护有更大的需求。施用于皮肤的Q-10的同化作用发生相对快速,这是由接触的浓度和持续时间决定的。当向皮肤施用Q-10的乙醇溶液时,在穿透表皮的角质层后,约20%将到达表皮的存活部分并且约2%到达真皮。
除了它们的抗氧化性质,硫辛酸和Q-10都在细胞的能量产出中具有基本的作用。硫辛酸存在于线粒体柠檬酸循环的若干酶系统中。已显示补充硫辛酸会改善线粒体的性能并且能逆转一些涉及老化的过程。Q-10构成了电子传递链的一部分,在那里此物质会提高电子传输能力和细粒体内膜的电位。
包含在本发明的膏霜中的另一种物质是乙酰肉毒碱。乙酰肉毒碱被包含在膏霜中是因为它能以催化量恢复线粒体的脂肪酸氧化,其在老化的线粒体中被削弱。
在控制(conrrolled)研究中,Q-10在某些程度上已经显示出对于光损伤性皮肤起作用。已发现乙酰肉毒碱被使用于各种皮肤护理产品中,但是没有任何其对于光损伤性皮肤作用的报道。在开放的非控制临床试验中已经显示在某一程度上硫辛酸对于光损伤性皮肤起作用。
以特定的量组合硫辛酸,Q-10和乙酰肉毒碱会产生不寻常的协同效应,与在一种和相同的赋形剂中独立地含有硫辛酸和独立地含有Q-10和乙酰肉毒碱相比,所有这三种物质的组合对于光损伤性皮肤产生了提高的作用。
本发明描述的膏霜包含基于水的赋形剂,其已经被特别地发展来分散和乳化硫辛酸,Q-10和乙酰肉毒碱。此外,赋形剂组分的目标是使膏霜具有合适的稠度,并作为软化剂和保湿剂。为获得所述的协同作用合适的制剂具有如下成分:0.5-7%重量的d,1-α-硫辛酸,优选5.0%重量,0.05-0.5%重量的辅酶Q-10,其中0.3%重量是好的平衡量,0.01-3%重量的乙酰-1-肉毒碱盐酸盐,其中0.03%重量是好的平衡量,且这些是被包含在构成上述提及的成分的基础处方理想的赋形剂中,所述赋形剂包含20-80%重量的水,其中46.32%重量是平衡重量,5-50%重量的在2%水溶液中的黄原胶,其中15.0%重量是平衡量,1-40%重量的辛酸/癸酸的甘油三酸酯,其中13.0%重量是平衡量,1-25%重量的Prunus dulcis油,其中4.0%重量是平衡量,0.5-10%重量的PEG-75硬脂酸盐,其中3.3%重量是平衡量,0.5-10%重量的硬脂酸甘油酯,其中2.7%重量是平衡量,1-10%重量的十六/十八醇(cetearyl),其中3.0%重量是平衡量,1-10%重量的二甲基硅油,其中3.0%重量是平衡量,1-15%重量的甘油,其中3.0%是平衡量,0.1-1.0%重量的苯氧乙醇,其中0.355%重量是平衡量,0.05-1.0%重量的对羟基苯甲酸甲酯,其中0.085%重量是平衡量,0.005-0.5%重量的对羟基苯甲酸丁酯,其中0.02%重量是平衡量,0.005-0.5%重量的对羟基苯甲酸乙酯,其中0.02%重量是平衡量,0.005-0.5%重量的对羟基苯甲酸丙酯,其中0.01%重量是平衡量,0.005-0.5%重量的对羟基苯甲酸异丁酯,其中0.01%重量是平衡量,0.05-5%重量的在10%水溶液中的氢氧化钠,其中0.4%重量是平衡量,0.05-5%重量的香料,其中0.25%重量是平衡量和0.05-5%重量的卡波姆,其中0.2%重量是平衡量。
在Karolinska医院皮肤科有资格的人员的参与下,进行了常规的临床试验来在临床上确定此膏霜对于面部皮肤结构的影响。此研究包括32名年龄在40-75岁之间的女性病人,她们具有按照Fitzpatrick的相应的皮肤类型I,II和III(阳光-反应性皮肤类型I-VI的有效性和实用性,Archives of dermatology,124卷,869-871页,1988年6月)。随机在病人脸的左侧或右侧施用编号的verum膏霜并在脸的另一侧施用对照膏霜。verum膏霜与本发明的组成一致,对照膏霜除了不含硫辛酸也具有相同的组成。在试验期的十二个星期中,每天早晚施用膏霜。在试验开始时,由受过培训的研究护士在脸的左侧和右侧分别制作硅复制品(除了眼角)。由专门的皮肤摄影师给每个病人拍照并由医生评价有关的十一个不同方面。医生在五个不同的时机重复评估,最后一次是在试验期结束时。在试验期结束时也由相同的专业人员重复制作硅复制品和照相。
将在试验期结束时由医生作出的评估与在试验开始时作出的评估相比较(临床评估)。也用照相比较进行相同的程序(照相评估)。利用激光面形测定器比较在试验期结束时的硅复制品和相应的试验期开始时的复制品(激光面形测定测量)。计算机辅助激光面形测定器是用于定量地分析皮肤表面结构变化的客观系统。最终参与者利用在试验期中四个时机的评价形式来评价治疗的结果,最后一次是在试验期结束时。
全面履行的临床和照相评估以及自我-评估分级使用下面的等级:1=较差,2=无可识别的变化,3=略微可见/可见改善,4=中等-显而易见的改善,5=显著的-非常显著的改善。激光面形测定测量显示与最初值相比以百分比计算的变化。在试验结果的评价中使用Wilcoxon’s配对试验。结果显示在图1-图4中,图1(自我评价)p=0.0015,图2(照相评价)p=0.025,图3(临床评价)p=0.033,图4(激光面形测定测量)p<0.001。
Claims (4)
1.用于局部治疗由某些自由基作用过程引起的可见光损伤的面霜,这其中的活性成分由膏霜赋形剂承载,其特征在于0.5-7%重量的d,1-α-硫辛酸,0.05-0.5%重量的辅酶Q-10和0.01-3%重量的乙酰-1-肉毒碱盐酸盐组成活性成分。
2.根据权利要求1的面霜,其特征在于其包括5%重量的d,1-α-硫辛酸,0.3%重量的辅酶Q-10和0.03%重量的乙酰-1-肉毒碱盐酸盐。
3.根据权利要求1的面霜,其特征在于其包括1%重量的d,1-α-硫辛酸,0.3%重量的辅酶Q-10和0.03%重量的乙酰-1-肉毒碱盐酸盐。
4.根据权利要求1的面霜,其中所述霜采用下面步骤的方法制备:在与膏霜其余的成分混合之前,先将活性成分d,1-α-硫辛酸溶解在辛酸/癸酸的甘油三酸酯中,
然后将溶解的d,1-α-硫辛酸和辛酸/癸酸的甘油三酸酯的混合物加入到膏霜赋形剂中。
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0102380A SE0102380D0 (sv) | 2001-07-02 | 2001-07-02 | Kräm för behandling av åldersförändringar i huden hos människa |
SE01023803 | 2001-07-02 | ||
SE0102380-3 | 2001-07-02 | ||
PCT/SE2002/001308 WO2003037291A1 (en) | 2001-07-02 | 2002-06-30 | Cream for treatment of skin injured by the sun |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1713888A CN1713888A (zh) | 2005-12-28 |
CN1713888B true CN1713888B (zh) | 2011-01-26 |
Family
ID=20284723
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN028131169A Expired - Lifetime CN1713888B (zh) | 2001-07-02 | 2002-06-30 | 用于治疗被太阳损伤的皮肤的膏霜 |
Country Status (20)
Country | Link |
---|---|
US (2) | US20050152856A2 (zh) |
EP (1) | EP1411889B1 (zh) |
JP (1) | JP2005507406A (zh) |
KR (1) | KR100885347B1 (zh) |
CN (1) | CN1713888B (zh) |
AT (1) | ATE349998T1 (zh) |
AU (1) | AU2002318699B2 (zh) |
BR (1) | BR0210760A (zh) |
CA (1) | CA2450726A1 (zh) |
CY (1) | CY1107600T1 (zh) |
DE (1) | DE60217356T2 (zh) |
DK (1) | DK1411889T3 (zh) |
ES (1) | ES2280554T3 (zh) |
MX (1) | MXPA03011509A (zh) |
NO (1) | NO20035715D0 (zh) |
NZ (1) | NZ530226A (zh) |
PT (1) | PT1411889E (zh) |
RU (1) | RU2313333C2 (zh) |
SE (1) | SE0102380D0 (zh) |
WO (1) | WO2003037291A1 (zh) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2858932B1 (fr) * | 2003-08-22 | 2009-10-30 | Oreal | Composition destinee a lutter contre la degradation des fibres de collagene induite en condition d'exposition solaire naturelle |
MXPA06008293A (es) | 2004-01-22 | 2007-06-11 | Univ Miami | Formulaciones topicas de coenzima q10 y metodos de uso. |
US7776915B2 (en) * | 2005-03-24 | 2010-08-17 | Tracie Martyn International, Llc | Topical formulations and methods of use |
CN1723881A (zh) * | 2005-06-23 | 2006-01-25 | 马开龙 | 含辅酶q10的治疗皮肤病的组合物及其制备方法 |
CA2823407C (en) | 2007-03-22 | 2016-10-18 | Berg Pharma Llc | Topical formulations having enhanced bioavailability |
US7999040B2 (en) * | 2007-09-25 | 2011-08-16 | Nanochem Solutions, Inc. | Method of making graft copolymers from sodium poly(aspartate) and the resulting graft copolymer |
CA2719658C (en) | 2008-04-01 | 2019-10-01 | Antipodean Pharmaceuticals, Inc. | Compositions and methods for skin care |
CA2721071C (en) | 2008-04-11 | 2017-10-17 | Cytotech Labs, Llc | Methods and use of inducing apoptosis in cancer cells |
KR101553074B1 (ko) | 2008-07-17 | 2015-09-14 | 가천대학교 산학협력단 | 나노에멀젼 조성물 |
JP6081195B2 (ja) | 2009-05-11 | 2017-02-15 | バーグ エルエルシー | エピメタボリックシフター、多次元細胞内分子、または環境影響因子を使用する腫瘍性障害の診断のための方法 |
EP2544663B1 (en) | 2010-03-12 | 2018-01-03 | Berg LLC | Intravenous formulations of coenzyme q10 (coq10) and methods of use thereof |
CN103608323B (zh) | 2011-04-04 | 2016-08-17 | 博格有限责任公司 | 治疗中枢神经系统肿瘤的方法 |
PE20180414A1 (es) | 2011-06-17 | 2018-03-01 | Berg Llc | Composiciones farmaceuticas inhalables |
US10933032B2 (en) | 2013-04-08 | 2021-03-02 | Berg Llc | Methods for the treatment of cancer using coenzyme Q10 combination therapies |
IL276423B2 (en) | 2013-09-04 | 2024-05-01 | Berg Llc | Pharmaceutical preparations containing coenzyme Q10 for use in cancer treatment |
SE543528C2 (en) * | 2019-04-04 | 2021-03-16 | Medica Clinical Nord Sverige Ab | Cream for treatment of skin injured by the sun |
WO2020201377A1 (en) | 2019-04-04 | 2020-10-08 | Medica Clinical Nord Sverige Ab | Cream for treatment of skin injured by the sun |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19806947A1 (de) * | 1998-02-19 | 1999-08-26 | Beiersdorf Ag | Kosmetische oder dermatologische Wirkstoffkombinationen aus mindestens einer Substanz gewählt aus der Gruppe, bestehend aus Carnitin und den Acylcarnitinen, und mindestens einem Chinon und oder mindestens einem Hydrochinon sowie Zubereitungen mit einem Gehalt an solchen Wirkstoffkombinationen |
EP0945127A2 (de) * | 1998-02-19 | 1999-09-29 | Beiersdorf Aktiengesellschaft | Verwendung von Acyl-Carnitin |
WO2000053176A1 (en) * | 1999-03-05 | 2000-09-14 | Uni-Ci S.R.L. | Pharmaceutic, dietetic and cosmetic compositions based on thioctic acid and cysteine |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS62175415A (ja) * | 1986-01-27 | 1987-08-01 | Kanebo Ltd | 皮膚化粧料 |
JP2794433B2 (ja) * | 1989-02-02 | 1998-09-03 | 丸善製薬株式会社 | 甘草疎水性フラボノイド製剤 |
DE4410238A1 (de) * | 1994-03-25 | 1995-09-28 | Beiersdorf Ag | Hautpflegemittel |
WO1997002041A1 (en) * | 1995-07-03 | 1997-01-23 | Crandall Wilson T | Transdermal and oral treatment of androgenic alopecia |
DE19537027A1 (de) * | 1995-10-05 | 1997-04-10 | Beiersdorf Ag | Hautpflegemittel für alte Haut |
US5667791A (en) | 1996-05-31 | 1997-09-16 | Thione International, Inc. | X-ray induced skin damage protective composition |
US5977162A (en) * | 1996-09-16 | 1999-11-02 | Seidman; Michael D. | Therapeutic treatment for auditory function |
US6015548A (en) * | 1998-07-10 | 2000-01-18 | Shaklee Corporation | High efficiency skin protection formulation with sunscreen agents and antioxidants |
US6013270A (en) * | 1998-04-20 | 2000-01-11 | The Procter & Gamble Company | Skin care kit |
AU756691B2 (en) * | 1998-04-24 | 2003-01-23 | Procter & Gamble Company, The | Cleansing articles for skin and/or hair which also deposits skin care actives |
JP2000063273A (ja) * | 1998-08-20 | 2000-02-29 | Noevir Co Ltd | 免疫機能低下抑制剤 |
IT1302307B1 (it) * | 1998-09-01 | 2000-09-05 | Sigma Tau Healthscience Spa | Composizione ad attivita' antiossidante ed atta a migliorarel'utilizzazione metabolica del glucosio, comprendente acetil |
US6048886A (en) | 1998-10-05 | 2000-04-11 | Neigut; Stanley | Compositions and delivery systems for the topical treatment of psoriasis and other conditions of the skin |
US6573299B1 (en) * | 1999-09-20 | 2003-06-03 | Advanced Medical Instruments | Method and compositions for treatment of the aging eye |
US20020044913A1 (en) | 2000-02-11 | 2002-04-18 | Hamilton Nathan D. | Cosmetics to support skin metabolism |
DE10020874A1 (de) * | 2000-04-28 | 2001-05-17 | Murnauer Markenvertrieb Gmbh | Kosmetisch-pharmazeutisches Kombinationspräparat |
ATE320833T1 (de) * | 2000-06-06 | 2006-04-15 | Verwendung von einem liponsaüren -(r)- enantiomeren in kosmetika und dermatologie | |
DE10036797A1 (de) * | 2000-07-28 | 2002-02-07 | Beiersdorf Ag | Verwendung von Kombinationen mit einem Gehalt an Carnitinen |
DE10036798A1 (de) * | 2000-07-28 | 2002-02-07 | Beiersdorf Ag | Mittel zur Behandlung der Haare und der Kopfhaut |
DE10059584A1 (de) * | 2000-11-30 | 2002-06-06 | Beiersdorf Ag | Kosmetische oder dermatologische getränkte Tücher |
US20020119114A1 (en) * | 2000-12-18 | 2002-08-29 | Beiersdorf Aktiengesellschaft | Active ingredient combinations of surface-active citric esters and alpha-lipoic acid, and cosmetic and dermatological preparations containing such mixtures |
US6300377B1 (en) * | 2001-02-22 | 2001-10-09 | Raj K. Chopra | Coenzyme Q products exhibiting high dissolution qualities |
DE10111048A1 (de) * | 2001-03-06 | 2002-09-12 | Beiersdorf Ag | Verwendung von alpha-Liponsäure zur Herstellung kosmetischer oder dermatologischer Zubereitungen zur Regeneration beanspruchter Haut, insbesondere der gealterten Haut |
US20030167556A1 (en) * | 2002-03-05 | 2003-09-11 | Consumers Choice Systems, Inc. | Methods and devices for transdermal delivery of anti-aging compounds for treatment and prevention of facial or neck skin aging |
-
2001
- 2001-07-02 SE SE0102380A patent/SE0102380D0/xx unknown
-
2002
- 2002-06-30 AU AU2002318699A patent/AU2002318699B2/en not_active Expired
- 2002-06-30 WO PCT/SE2002/001308 patent/WO2003037291A1/en active IP Right Grant
- 2002-06-30 ES ES02747792T patent/ES2280554T3/es not_active Expired - Lifetime
- 2002-06-30 NZ NZ530226A patent/NZ530226A/en not_active IP Right Cessation
- 2002-06-30 MX MXPA03011509A patent/MXPA03011509A/es active IP Right Grant
- 2002-06-30 RU RU2003137600/15A patent/RU2313333C2/ru not_active IP Right Cessation
- 2002-06-30 EP EP02747792A patent/EP1411889B1/en not_active Expired - Lifetime
- 2002-06-30 PT PT02747792T patent/PT1411889E/pt unknown
- 2002-06-30 JP JP2003539635A patent/JP2005507406A/ja active Pending
- 2002-06-30 DE DE60217356T patent/DE60217356T2/de not_active Expired - Lifetime
- 2002-06-30 DK DK02747792T patent/DK1411889T3/da active
- 2002-06-30 KR KR1020037017319A patent/KR100885347B1/ko active IP Right Grant
- 2002-06-30 CA CA002450726A patent/CA2450726A1/en not_active Abandoned
- 2002-06-30 BR BR0210760-0A patent/BR0210760A/pt not_active Application Discontinuation
- 2002-06-30 AT AT02747792T patent/ATE349998T1/de not_active IP Right Cessation
- 2002-06-30 CN CN028131169A patent/CN1713888B/zh not_active Expired - Lifetime
-
2003
- 2003-12-19 NO NO20035715A patent/NO20035715D0/no not_active Application Discontinuation
-
2004
- 2004-06-21 US US10/482,694 patent/US20050152856A2/en not_active Abandoned
-
2006
- 2006-12-21 US US11/642,948 patent/US20070212431A1/en not_active Abandoned
-
2007
- 2007-03-26 CY CY20071100415T patent/CY1107600T1/el unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19806947A1 (de) * | 1998-02-19 | 1999-08-26 | Beiersdorf Ag | Kosmetische oder dermatologische Wirkstoffkombinationen aus mindestens einer Substanz gewählt aus der Gruppe, bestehend aus Carnitin und den Acylcarnitinen, und mindestens einem Chinon und oder mindestens einem Hydrochinon sowie Zubereitungen mit einem Gehalt an solchen Wirkstoffkombinationen |
EP0945127A2 (de) * | 1998-02-19 | 1999-09-29 | Beiersdorf Aktiengesellschaft | Verwendung von Acyl-Carnitin |
WO2000053176A1 (en) * | 1999-03-05 | 2000-09-14 | Uni-Ci S.R.L. | Pharmaceutic, dietetic and cosmetic compositions based on thioctic acid and cysteine |
Also Published As
Publication number | Publication date |
---|---|
US20050152856A2 (en) | 2005-07-14 |
ES2280554T3 (es) | 2007-09-16 |
KR100885347B1 (ko) | 2009-02-26 |
WO2003037291A8 (en) | 2004-05-13 |
DE60217356D1 (de) | 2007-02-15 |
EP1411889A1 (en) | 2004-04-28 |
CY1107600T1 (el) | 2013-03-13 |
DE60217356T2 (de) | 2007-10-11 |
CN1713888A (zh) | 2005-12-28 |
MXPA03011509A (es) | 2004-10-28 |
AU2002318699B2 (en) | 2007-01-04 |
RU2313333C2 (ru) | 2007-12-27 |
CA2450726A1 (en) | 2003-05-08 |
US20040219114A1 (en) | 2004-11-04 |
US20070212431A1 (en) | 2007-09-13 |
KR20040030728A (ko) | 2004-04-09 |
WO2003037291A1 (en) | 2003-05-08 |
EP1411889B1 (en) | 2007-01-03 |
SE0102380D0 (sv) | 2001-07-02 |
DK1411889T3 (da) | 2007-05-07 |
NO20035715D0 (no) | 2003-12-19 |
ATE349998T1 (de) | 2007-01-15 |
PT1411889E (pt) | 2007-04-30 |
JP2005507406A (ja) | 2005-03-17 |
RU2003137600A (ru) | 2005-03-27 |
BR0210760A (pt) | 2004-07-20 |
NZ530226A (en) | 2005-08-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1713888B (zh) | 用于治疗被太阳损伤的皮肤的膏霜 | |
JP7300988B2 (ja) | 外用組成物 | |
JP2017114814A (ja) | 化粧料 | |
AU2002318699A1 (en) | Cream for treatment of skin injured by the sun | |
JP2004091376A (ja) | 表皮角化正常化剤及びこれを含有する皮膚外用剤 | |
JP2003221328A (ja) | 皮膚健全化剤 | |
WO2017100873A1 (pt) | Composição cosmética e seu uso | |
JP2001131049A (ja) | 皮膚外用剤 | |
CN110302090A (zh) | L-5-甲基四氢叶酸氨基葡萄糖盐在化妆品中的应用 | |
KR102159664B1 (ko) | 주름 개선제 | |
JP2005263638A (ja) | シワ改善剤 | |
KR101145814B1 (ko) | 주름 개선용 조성물 | |
WO2020201377A1 (en) | Cream for treatment of skin injured by the sun | |
JP4488933B2 (ja) | シワ改善剤及び皮膚外用組成物 | |
KR101526592B1 (ko) | 피부주름 개선용 조성물 | |
KR20100033729A (ko) | N-아세틸글루코사민과 비타민 c를 함유하는 화장료 조성물 | |
JP2001354518A (ja) | 皮膚外用剤 | |
LV15082B (lv) | Krēms sejas ādas, kakla un dekoltē zonas epidermālās lipīdu barjeras atjaunošanai pacientiem ar metabolisko sindromu | |
TWI571267B (zh) | 一種組合物用於製備具有保濕功能的醫學美容化妝品之用途 | |
CN115414265A (zh) | 一种具有修色、嫩肤、保湿功效的组合物、面霜及其制备方法 | |
CN118175986A (zh) | 皮肤外用组合物及其利用、以及皮肤外用组合物原料 | |
JP2007277134A (ja) | インターロイキン−6産生抑制剤 | |
Fluhr et al. | Penetration properties and safety aspects of topically applied products | |
JP2008094819A (ja) | 浸透性化粧料組成物 | |
BR102017010610B1 (pt) | Composição cosmética, método para o cuidado da pele, uso cosmético e produto cosmético para o cuidado da pele |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20200715 Address after: Sweden Yan Xueping Patentee after: Nord medical clinic Ltd. Address before: Sundsvall Patentee before: MACRONOVA AB |
|
CX01 | Expiry of patent term | ||
CX01 | Expiry of patent term |
Granted publication date: 20110126 |